Return to Travel in the Coronavirus Disease 2019 Pandemic Recovery Period and Implications for Imported Malaria: Reinforcing Prevention, Early Diagnosis, and Appropriate Treatment of Malaria

Details

• Alternative Title:
  Clin Infect Dis
• Personal Author:
  Schultz, Jonathan S. ; Mace, Kimberly E. ; Tan, Kathrine R.
• Description:
  Return to international travel in the COVID-19 pandemic recovery period is expected to increase the number of patients with imported malaria in the United States (US). Malaria prevention in travelers and preparedness for timely diagnosis and appropriate treatment are key to minimize imported malaria morbidity and mortality. Intravenous artesunate (IVAS) is now available from commercial distributors in the US for the treatment of severe malaria. Hospitals and pharmacists should have a plan for malaria treatment, including stocking artemether-lumefantrine for uncomplicated malaria, and stocking or planning for rapid procurement of IVAS for the treatment of severe malaria.
• Subjects:
  • Humans
  • United States
  • Antimalarials
  • Pandemics
  • Artemether
  • Artemether, Lumefantrine Drug Combination
  • COVID-19
  • Malaria
  • Artesunate
  • Travel
  More +
• Keywords:
  • malaria
  • travel
  • artesunate
  • Plasmodium falciparum
  • chemoprophylaxis
• Source:
  Clin Infect Dis. 76(7):1161-1163
• Pubmed ID:
  36723870
• Pubmed Central ID:
  PMC10450225
• Document Type:
  Journal Article
• Funding:
  CC999999/ImCDC/Intramural CDC HHSUnited States/
• Volume:
  76
• Issue:
  7
• Download URL:
  https://stacks.cdc.gov/view/cdc/132372/cdc_132372_DS1.pdf
• File Type:
  [PDF - 494.61 KB]
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:6a5716e8f8b2da00e128c8a523ea151b9022d82790736fd2c8d795ce66356913